GLP-1 analogue liraglutide enhances SP-a expression in LPS-induced acute lung injury through the TTF-1 signaling pathway
NADPH oxidase subunit, gp91(phox) homologue, preferentially expressed in human colon epithelial cells
However, multiple forces are converging to limit their future: 1
Non-approved Therapies for Obesity Incretin-based Treatments Since the isolation of the peptide exendin-4 from Heloderma suspectum (Gila Monster) lizard venom in 1992 [25], several drugs that manipulate the incretin axis have been produced and approved for use in people with T2D including exenatide (2005), liraglutide (2009), lixisenatide (2013), albiglutide (2014, withdrawn 2017), dulaglutide (2014) and semaglutide (2017) [26]
Table of Contents What Is Non-Alcoholic Fatty Liver Disease (NAFLD)
This drug is part of the glucagon-like peptide-1 (GLP-1) receptor agonists class of medications